Bioterrorism-related inhalational anthrax: Can extrapolated adult guidelines be applied to a pediatric population?

被引:2
|
作者
Place, Rick C.
Hanfling, Dan
Howell, John M.
Mayer, Thom A.
机构
[1] Inova Fairfax Hosp, Dept Emergency Med, Falls Church, VA 22042 USA
[2] George Washington Univ, Dept Emergency Med, Washington, DC USA
[3] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
关键词
D O I
10.1089/bsp.2006.0011
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective. Since the 2001 anthrax attacks, an extensive body of literature has evolved, but there has been a limited focus on the management of pediatric-specific issues. We looked at the symptom complexes of all pediatric patients presenting to the emergency department of our hospital during this period and examined whether their presentations would likely allow current guidelines to be used as potential screening criteria to identify children infected with anthrax. Methods. We retrospectively reviewed emergency department records of all adult and pediatric patients (up to the age of 21 years) at Inova Fairfax Hospital during this time, when a large, and at the time ill-defined, group in the Washington, DC, metropolitan area was at risk for pulmonary anthrax. Two cases of anthrax infection were identified at this hospital in exposed adult postal workers. Screening algorithms (described by Mayer et al. and Hupert et al.) were applied to adult and pediatric patients with the presence of fever (38 degrees C), tachycardia, or other symptoms compatible with pulmonary anthrax. Specifically, the usefulness of these guidelines as potential screening tools to identify possibly infected children was examined. Results. Of 767 pediatric patients seen in the emergency department during the study period, 312 met criteria for review (41%; 95% CI : 37-44%). Four adult patients (0.4%; 95% CI : 0.1-0.9%) had at least five clinical symptoms, fever, and tachycardia; two of them had inhalational anthrax. No pediatric patient presented with five or more clinical symptoms. Twelve children (3.9%; 95% CI : 2-6.6%) presented with four clinical symptoms; five of the 12 had neither fever nor tachycardia. Children, particularly infants and toddlers, presented with nonspecific symptom complexes primarily limited to fever, vomiting, cough, and trouble breathing. Conclusions: Existing guidelines are likely to be unreliable as a screening tool for inhalational anthrax in children, largely because of the children's inability to adequately communicate a suggestive symptom complex.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 50 条
  • [21] Call-tracking data and the public health response to bioterrorism-related anthrax
    Mott, JA
    Treadwell, TA
    Hennessy, TW
    Rosenberg, PA
    Wolfe, MI
    Brown, CM
    Butler, JC
    EMERGING INFECTIOUS DISEASES, 2002, 8 (10) : 1088 - 1092
  • [22] Laboratory aspects of bioterrorism-related anthrax - from identification to molecular subtyping to microbial forensics
    Popovic, T
    Glass, M
    CROATIAN MEDICAL JOURNAL, 2003, 44 (03) : 336 - 341
  • [23] Detection and prevention of ocular phototoxicity of ciprofloxacin, the prophylactic antidote for bioterrorism-related anthrax.
    Roberts, JE
    Rammal, M
    Smith, F
    Hamilton, MG
    Chignell, CF
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U178 - U178
  • [24] Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax
    Quinn, CP
    Dull, PM
    Semenova, V
    Li, H
    Crotty, S
    Taylor, TH
    Steward-Clark, E
    Stamey, KL
    Schmidt, DS
    Stinson, KW
    Freeman, AE
    Elie, CM
    Martin, SK
    Greene, C
    Aubert, RD
    Glidewell, J
    Perkins, BA
    Ahmed, R
    Stephens, DS
    JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (07): : 1228 - 1236
  • [25] Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax (Reprinted from MMWR, vol 50, pg 941-948, 2001)
    Malecki, J
    Wiersma, S
    Cahill, T
    Grossman, M
    Hochman, H
    Tapper, M
    Pomeranz, M
    Friedman-Kien, A
    Gurtman, A
    Bresnitz, E
    DiFerdinando, G
    Lurie, P
    Nalluswami, K
    Frank, D
    Siegel, L
    Adams, S
    Walks, I
    Davies-Coles, J
    Chiriboga, C
    Brechner, R
    Peterson, E
    Bresoff-Matcha, S
    Galbraith, M
    Eisold, J
    Martin, G
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (19): : 2392 - 2396
  • [26] Systematic Review of Hospital Treatment Outcomes for Naturally Acquired and Bioterrorism-Related Anthrax, 1880-2018
    Person, Marissa K.
    Cook, Rachel
    Bradley, John S.
    Hupert, Nathaniel
    Bower, William A.
    Hendricks, Katherine
    CLINICAL INFECTIOUS DISEASES, 2022, 75 : S392 - S401
  • [27] Patients' request for and emergency physicians' prescription of antimicrobial prophylaxis for anthrax during the 2001 bioterrorism-related outbreak
    Nkuchia M M'ikanatha
    Kathleen G Julian
    Allen R Kunselman
    Robert C Aber
    James T Rankin
    Ebbing Lautenbach
    BMC Public Health, 5
  • [28] Patients' request for and emergency physicians' prescription of antimicrobial prophylaxis for anthrax during the 2001 bioterrorism-related outbreak
    M'ikanatha, NM
    Julian, KG
    Kunselman, AR
    Aber, RC
    Rankin, JT
    Lautenbach, E
    BMC PUBLIC HEALTH, 2005, 5 (1)
  • [29] Inhalational anthrax due to bioterrorism: Would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001?
    Mayer, TA
    Morrison, A
    Bersoff-Matcha, S
    Druckenbrod, G
    Murphy, C
    Howell, J
    Hanfling, D
    Cates, R
    Pauze, D
    Earls, J
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (10) : 1275 - 1283